Sarepta Therapeutics | SRPT - Interest Expense On Debt



Sarepta Therapeutics reported $5.23M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.


Interest Expense On Debt Change Date
Acadia Pharmaceuticals 0 4.12M Sep/2024
Agios Pharmaceuticals 3.01M 10.05M Dec/2024
Alnylam Pharmaceuticals USD 40.25M 1.6M Jun/2025
Amgen USD 694M 29M Jun/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.68M 184K Jun/2025
Daiichi Sankyo 1.42B 5.66B Jun/2025
Eli Lilly USD 249M 5.3M Jun/2025
Gilead Sciences USD 254M 6M Jun/2025
Incyte USD 594K 66K Jun/2025
Insmed USD 21.24M 1.5M Jun/2025
Ionis Pharmaceuticals USD 19M 0 Jun/2025
Moderna USD 1000K 0 Jun/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Pfizer USD 654M 0 Jun/2025
PTC Therapeutics USD 30.36M 4.03M Jun/2025
Regeneron Pharmaceuticals USD 3.6M 5.1M Jun/2025
Roche Holding CHF 311.5M 1000K Dec/2024
Sanofi 148M 65M Jun/2025
Sarepta Therapeutics USD 5.23M 725K Jun/2025
Tectonic Therapeutic USD 17K 5K Jun/2025
Ultragenyx Pharmaceutical 14.04M 1.48M Jun/2025
Vertex Pharmaceuticals USD 3.7M 900K Jun/2025